Abstract | OBJECTIVE: METHODS: RESULTS:
NT-proBNP demonstrated a strong graded relationship with CV outcomes, including CV death (p for trend < 0.0001), myocardial infarction (MI) (p for trend = 0.02), heart failure (HF) (p for trend < 0.0001), and a composite of thrombotic events (CV death, MI, stroke) or HF (p for trend < 0.0001). Baseline levels of hsCRP were not associated with CV events (CV death/MI/ stroke/HF; p for trend = 0.65). NT-proBNP remained strongly predictive of CV events after adjustment for age, sex, diabetes, hypertension, hyperlipidemia, smoking, type of arthritis, body mass index, creatinine clearance, history of CV disease, and hsCRP (CV death/MI/ stroke/HF: Q4 vs Q1 hazard ratio 3.53, 95% CI 1.89-6.58). Patients with a NT-proBNP level below 100 pg/ml had a 0.94% rate of thrombotic events or heart failure at 2 years. CONCLUSION:
|
Authors | Christian T Ruff, David A Morrow, Peter Jarolim, Fang Ren, Charles F Contant, Amarjot Kaur, Sean P Curtis, Loren Laine, Christopher P Cannon, Kay Brune |
Journal | The Journal of rheumatology
(J Rheumatol)
Vol. 38
Issue 6
Pg. 1071-8
(Jun 2011)
ISSN: 0315-162X [Print] Canada |
PMID | 21459935
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Biomarkers
- Peptide Fragments
- Pyridines
- Sulfones
- pro-brain natriuretic peptide (1-76)
- Natriuretic Peptide, Brain
- Diclofenac
- C-Reactive Protein
- Etoricoxib
|
Topics |
- Aged
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Arthritis, Rheumatoid
(blood, drug therapy)
- Biomarkers
(blood)
- C-Reactive Protein
(metabolism)
- Cardiovascular Diseases
(epidemiology)
- Diclofenac
(therapeutic use)
- Etoricoxib
- Female
- Heart Failure
(epidemiology)
- Humans
- Longitudinal Studies
- Male
- Middle Aged
- Myocardial Infarction
(epidemiology)
- Natriuretic Peptide, Brain
(blood)
- Osteoarthritis
(blood, drug therapy)
- Peptide Fragments
(blood)
- Prospective Studies
- Pyridines
(therapeutic use)
- Retrospective Studies
- Risk Factors
- Sulfones
(therapeutic use)
- Thrombosis
- Treatment Outcome
|